Arbutus Biopharma Corporation Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ABUS
  • CUSIP: N/A
  • Web: www.arbutusbio.com
Capitalization:
  • Market Cap: $203.6 million
  • Outstanding Shares: 55,026,000
Average Prices:
  • 50 Day Moving Avg: $3.67
  • 200 Day Moving Avg: $3.32
  • 52 Week Range: $2.35 - $4.04
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.06
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.85 million
  • Price / Sales: 110.05
  • Book Value: $3.19 per share
  • Price / Book: 1.16
Profitability:
  • EBIDTA: ($65,740,000.00)
  • Return on Equity: -28.97%
  • Return on Assets: -21.71%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 8.92%
  • Quick Ratio: 8.92%
Misc:
  • Average Volume: 96,530 shs.
  • Beta: 0.96
  • Short Ratio: 9.83
 

Frequently Asked Questions for Arbutus Biopharma Corporation (NASDAQ:ABUS)

What is Arbutus Biopharma Corporation's stock symbol?

Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma Corporation's earnings last quarter?

Arbutus Biopharma Corporation (NASDAQ:ABUS) posted its earnings results on Thursday, November, 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.11. The business earned $4.10 million during the quarter, compared to the consensus estimate of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.

When will Arbutus Biopharma Corporation make its next earnings announcement?

Arbutus Biopharma Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Arbutus Biopharma Corporation.

Where is Arbutus Biopharma Corporation's stock going? Where will Arbutus Biopharma Corporation's stock price be in 2017?

5 equities research analysts have issued twelve-month price objectives for Arbutus Biopharma Corporation's stock. Their predictions range from $6.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's share price to reach $16.00 in the next year. View Analyst Ratings for Arbutus Biopharma Corporation.

What are analysts saying about Arbutus Biopharma Corporation stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:

  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (7/10/2017)
  • 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Who are some of Arbutus Biopharma Corporation's key competitors?

Who are Arbutus Biopharma Corporation's key executives?

Arbutus Biopharma Corporation's management team includes the folowing people:

  • Vivek Ramaswamy, Chairman of the Board
  • Mark J. Murray Ph.D., President, Chief Executive Officer, Director
  • Bruce G. Cousins, Chief Financial Officer, Executive Vice President
  • Elizabeth Howard, Executive Vice President, General Counsel
  • Peter Lutwyche Ph.D., Chief Technology Officer
  • Michael Joseph Sofia, Chief Scientific Officer
  • William Thomas Symonds III, Chief Development Officer, Director
  • Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
  • Patrick T. Higgins, Chief Business Officer
  • Daniel D. Burgess, Director

Who owns Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (1.59%), AXA (1.42%), K2 Principal Fund L.P. (0.68%), Victory Capital Management Inc. (0.24%), Goldman Sachs Group Inc. (0.17%) and OxFORD Asset Management LLP (0.15%). Company insiders that own Arbutus Biopharma Corporation stock include Michael J Sofia and Richard C Henriques Jr. View Institutional Ownership Trends for Arbutus Biopharma Corporation.

Who sold Arbutus Biopharma Corporation stock? Who is selling Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., K2 Principal Fund L.P. and AXA. View Insider Buying and Selling for Arbutus Biopharma Corporation.

Who bought Arbutus Biopharma Corporation stock? Who is buying Arbutus Biopharma Corporation stock?

Arbutus Biopharma Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., OxFORD Asset Management LLP, Bank of Montreal Can and Vanguard Group Inc.. View Insider Buying and Selling for Arbutus Biopharma Corporation.

How do I buy Arbutus Biopharma Corporation stock?

Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma Corporation's stock price today?

One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $3.70.


MarketBeat Community Rating for Arbutus Biopharma Corporation (NASDAQ ABUS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  300
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corporation (NASDAQ:ABUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (332.43% upside)

Analysts' Ratings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/7/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
6/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$32.00LowView Rating Details
3/22/2017WedbushReiterated RatingOutperform$9.00 -> $10.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2015Royal Bank Of CanadaLower Price Target$20.00 -> $12.00N/AView Rating Details
(Data available from 8/22/2015 forward)

Earnings

Earnings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Earnings by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Earnings History by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.37)N/AView Earnings Details
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corporation (NASDAQ:ABUS)
2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.25)($0.30)
Q2 20173($0.42)($0.39)($0.40)
Q3 20173($0.43)($0.39)($0.41)
Q4 20173($0.44)($0.39)($0.42)
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.30)($0.30)($0.30)
Q3 20181($0.31)($0.31)($0.31)
Q4 20181($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 66.49%
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.00View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Source:
DateHeadline
americanbankingnews.com logo$790,000.00 in Sales Expected for Arbutus Biopharma Corporation (ABUS) This Quarter
www.americanbankingnews.com - August 22 at 11:40 AM
americanbankingnews.com logoInsider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:48 PM
finance.yahoo.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 16 at 8:23 PM
globenewswire.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 14 at 3:28 PM
finance.yahoo.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 14 at 3:28 PM
americanbankingnews.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - August 7 at 8:00 AM
seekingalpha.com logoArbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 8:29 PM
globenewswire.com logoArbutus Announces Corporate Update and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:24 PM
finance.yahoo.com logoEdited Transcript of ABUS earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 3:24 PM
americanbankingnews.com logoZacks: Analysts Expect Arbutus Biopharma Corporation (NASDAQ:ABUS) Will Announce Quarterly Sales of $680,000.00
www.americanbankingnews.com - August 4 at 7:22 AM
finance.yahoo.com logoArbutus Announces Corporate Update and Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 8:43 PM
bizjournals.com logoThe search for a cure: Bucks County biopharm firm expands its portfolio of potential hepatitis B therapies
www.bizjournals.com - August 2 at 8:21 PM
americanbankingnews.com logoZacks: Brokerages Expect Arbutus Biopharma Corporation (NASDAQ:ABUS) Will Post Earnings of -$0.35 Per Share
www.americanbankingnews.com - August 2 at 8:14 AM
globenewswire.com logoArbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 1 at 8:39 PM
finance.yahoo.com logoArbutus Announces Conference Call to Provide a Corporate Update and Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 8:39 PM
americanbankingnews.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 29 at 3:13 PM
seekingalpha.com logoArbutus Seeks To Eradicate Hep B - Seeking Alpha
seekingalpha.com - July 28 at 3:38 PM
streetinsider.com logoArbutus Biopharma (ABUS) Reports Conclusion of LNP License Agreement with Alexion (ALXN) - StreetInsider.com
www.streetinsider.com - July 27 at 3:37 PM
finance.yahoo.com logoArbutus Announces Conclusion of LNP License Agreement with Alexion
finance.yahoo.com - July 27 at 3:37 PM
americanbankingnews.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:20 AM
seekingalpha.com logoRisk-Adjusted Net Present Value For Arbutus Biopharma - Seeking Alpha
seekingalpha.com - July 19 at 3:36 PM
americanbankingnews.com logo$680,000.00 in Sales Expected for Arbutus Biopharma Corporation (ABUS) This Quarter
www.americanbankingnews.com - July 13 at 1:25 PM
americanbankingnews.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Expected to Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - July 11 at 9:38 AM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 11 at 12:52 AM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 2:56 PM
americanbankingnews.com logoShort Interest in Arbutus Biopharma Corporation (ABUS) Expands By 33.1%
www.americanbankingnews.com - June 30 at 7:19 AM
americanbankingnews.com logo Brokerages Anticipate Arbutus Biopharma Corporation (ABUS) Will Announce Quarterly Sales of $680,000.00
www.americanbankingnews.com - June 16 at 11:58 AM
americanbankingnews.com logo Analysts Anticipate Arbutus Biopharma Corporation (ABUS) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - June 15 at 12:44 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 9 at 2:16 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Research Coverage Started at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - June 2 at 7:30 PM
globenewswire.com logoArbutus Presents HBV Drug Combination Studies at ICAR - GlobeNewswire (press release)
globenewswire.com - May 23 at 5:31 AM
finance.yahoo.com logoArbutus Presents HBV Drug Combination Studies at ICAR
finance.yahoo.com - May 22 at 3:19 PM
finance.yahoo.com logoModerna Can't Escape My Intellectual Property, Says Arbutus CEO
finance.yahoo.com - May 16 at 3:17 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 15 at 12:47 PM
finance.yahoo.com logoArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 3:25 PM
bizjournals.com logo$10M move: How a company out to cure hepatitis B ended up in Warminster
www.bizjournals.com - May 9 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share
www.americanbankingnews.com - May 8 at 11:14 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 5 at 3:58 PM
finance.yahoo.com logoEdited Transcript of ABUS earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 3:17 PM
seekingalpha.com logoArbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:19 PM
finance.yahoo.com logoArbutus Announces Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 8:19 PM
finance.yahoo.com logoInvestor Network: Arbutus Biopharma Corporation to Host Earnings Call
finance.yahoo.com - May 4 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Receives News Sentiment Score of 0.12
www.americanbankingnews.com - May 3 at 8:28 AM
finance.yahoo.com logoArbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 3:22 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:10 AM
americanbankingnews.com logo$7.5 Million in Sales Expected for Arbutus Biopharma Corp (ABUS) This Quarter
www.americanbankingnews.com - April 29 at 9:51 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Earning Somewhat Favorable Media Coverage, Study Shows
www.americanbankingnews.com - April 27 at 9:32 AM
americanbankingnews.com logo Brokerages Expect Arbutus Biopharma Corp (ABUS) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 27 at 9:08 AM
streetinsider.com logoArbutus Biopharma (ABUS) Presents ARB-1467 Data Presentation ... - StreetInsider.com
www.streetinsider.com - April 24 at 3:18 PM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Earning Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 24 at 11:45 AM

Social

Chart

Arbutus Biopharma Corporation (ABUS) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by MarketBeat.com Staff